EGFR and non-small cell lung carcinoma: Combination treatments are also gaining attention; co-administration of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) with invariant NK T cells demonstrated acceptable safety and preliminary synergy in patients with EGFR-mutant NSCLC [9].